BioNJ announced it will move the location of its 14th Annual BioPartnering Conference, set for May 14, 2024, to the Liberty Science Center in Jersey City.
The annual event brings together life science executives, investors, academic collaborators and business development professionals from around the globe with a goal of fostering productive partnerships and facilitating investment opportunities. This year’s event was held at The Palace at Somerset Park – returning to an in-person format for the first time in three years.
In the Dec. 13 announcement, BioNJ said Liberty Science Center offers a spacious, state-of-the-art venue to accommodate the event, along with the innovative spirit that emanates from the facility, which has been in the news in recent days and weeks as part of the highly anticipated SciTech Scity project.
“We can’t think of a more exciting venue to host our 14th Annual BioPartnering Conference,” said Debbie Hart, president and CEO, BioNJ. “Entrepreneurs are the engine and fuel for new company creation – driving the next generation of therapies, diagnostics, and tools in life sciences. And, for the last three decades, the Liberty Science Center has nurtured young scientists and shepherded future leaders in its mission to foster new innovation. Jersey City is the perfect backdrop for this important meeting where life sciences companies, large and small, will gather to explore collaboration opportunities.”
BioNJ also announced that Jersey City Economic Development Corp. (JCEDC) will host the event, joining conference partners including J.P. Morgan, Johnson & Johnson Innovation and Morgan Lewis.
“We are grateful for Jersey City Economic Development Corp.’s support in bringing this important event to the Liberty Science Center in 2024,” said Hart.
She stressed that the mission of the conference is in complete alignment with that of Jersey City and the Liberty Science Center — to build a vibrant innovative hub.
“During this pivotal moment in Jersey City’s history, we are clearly making our mark in establishing Jersey City as a sought-after destination for transformative science and technology, and we welcome BioNJ as our newest partner on this front,” said Jersey City Mayor Steven Fulop, who also noted how grateful he was for the work of the JCEDC team and LSC President and CEO Paul Hoffman in making this partnership a reality.
“We look forward to welcoming BioNJ’s preeminent 2024 BioPartnering Conference to the Liberty Science Center and introducing attendees to SciTech Scity, the 30-acre innovation campus we are now building that will focus on home health care, biomedical science, planet care, and artificial intelligence (AI),” said Hoffman.
New Jersey Economic Development Authority (NJEDA) CEO Tim Sullivan said that Jersey City is quickly becoming a premier destination for inventive companies, which makes LSC the ideal location for this event.
“BioNJ’s annual BioPartnering Conference offers incredible opportunities to innovative New Jersey entrepreneurs and highlights the pioneering work of life sciences and technology companies in the state,” said Sullivan.
“BioNJ is honored to move this meeting to the Liberty Science Center which will allow us to showcase New Jersey’s innovative spirit and spotlight all that Jersey City, Liberty Science Center and SciTech Scity have to offer,” Hart added.
Also, this week, BioNJ announced details for another one of its marquee events – the Annual Dinner Meeting & Innovation Celebration, which will be held Feb. 8, 2024, at the Hilton East Brunswick.
At this year’s event, William Lewis, chair and CEO of Insmed, will be honored with the 2024 Dr. Sol J. Barer Award for Vision, Innovation, and Leadership. Named for the founder and former chairman and CEO of Celgene, and also a former BioNJ chairman, the distinction recognizes outstanding researchers and business leaders who have made significant contributions to the growth and prosperity of the life sciences industry in New Jersey and throughout the world.
“We are thrilled to announce that Will Lewis will be the recipient of the 2024 Dr. Sol J. Barer Award for his tireless work on behalf of patients, medical innovation, and New Jersey’s ever-growing life sciences ecosystem,” said Hart. “Mr. Lewis’ visionary thinking and transformative leadership have helped to redefine the biopharma landscape while revolutionizing patient care. Often pioneering the way for others to follow, Mr. Lewis is dedicated to bringing new, innovative therapies to patients while ensuring patients have access to the medicines they need when they need them.”
More information on BioNJ’s upcoming events and resources can be found here.